A Stanford study shows that in severely ill COVID-19 patients, ‘first-responder’ immune cells, which should react immediately to signs of viral or bacterial presence in the body, instead respond sluggishly.
- ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
- No benefit for post-operative radiotherapy in non-small-cell lung cancer
- First new drug in years reduces recurrence in high risk HR+ early breast cancer
- New first-line treatment option for metastatic kidney cancer
- UC study sheds light on cancer treatment, COVID-19